Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model
Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between...
Saved in:
Published in | Oncoimmunology Vol. 9; no. 1; p. 1758602 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Taylor & Francis
01.01.2020
Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8
+
tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic. |
---|---|
AbstractList | Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8
+
tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic. Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8 tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic. Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8+ tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic. |
Author | Waite, Janelle C. Murphy, Andrew J. Sleeman, Matthew A. Dhanik, Ankur Wei, Yi Ni, Min Adler, Christina Skokos, Dimitris Macdonald, Lynn E. Malahias, Evangelia Ye, Xuan Gupta, Namita Zhong, Maggie Zhang, Wen Gurer, Cagan |
Author_xml | – sequence: 1 givenname: Xuan surname: Ye fullname: Ye, Xuan organization: Regeneron Pharmaceuticals – sequence: 2 givenname: Janelle C. surname: Waite fullname: Waite, Janelle C. email: Janelle.waite@regeneron.com organization: Regeneron Pharmaceuticals – sequence: 3 givenname: Ankur surname: Dhanik fullname: Dhanik, Ankur organization: Regeneron Pharmaceuticals – sequence: 4 givenname: Namita surname: Gupta fullname: Gupta, Namita organization: Regeneron Pharmaceuticals – sequence: 5 givenname: Maggie surname: Zhong fullname: Zhong, Maggie organization: Regeneron Pharmaceuticals – sequence: 6 givenname: Christina surname: Adler fullname: Adler, Christina organization: Regeneron Pharmaceuticals – sequence: 7 givenname: Evangelia surname: Malahias fullname: Malahias, Evangelia organization: Regeneron Pharmaceuticals – sequence: 8 givenname: Min surname: Ni fullname: Ni, Min organization: Regeneron Pharmaceuticals – sequence: 9 givenname: Yi surname: Wei fullname: Wei, Yi organization: Regeneron Pharmaceuticals – sequence: 10 givenname: Cagan surname: Gurer fullname: Gurer, Cagan organization: Regeneron Pharmaceuticals – sequence: 11 givenname: Wen surname: Zhang fullname: Zhang, Wen organization: Regeneron Pharmaceuticals – sequence: 12 givenname: Lynn E. surname: Macdonald fullname: Macdonald, Lynn E. organization: Regeneron Pharmaceuticals – sequence: 13 givenname: Andrew J. surname: Murphy fullname: Murphy, Andrew J. organization: Regeneron Pharmaceuticals – sequence: 14 givenname: Matthew A. surname: Sleeman fullname: Sleeman, Matthew A. organization: Regeneron Pharmaceuticals – sequence: 15 givenname: Dimitris surname: Skokos fullname: Skokos, Dimitris email: dimitris.skokos@regeneron.com organization: Regeneron Pharmaceuticals |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32923116$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uk1v1DAUtFARLaU_AeQjly3-ipNcEKgqUKkSF5C4WY79snUV21vb2bL_HofdrugFX2y9NzPvyTOv0UmIARB6S8klJR35wKhkgrBfl4ywWmqbThL2Ap0t9dXSODm-KT1FFznfk3okaSTvX6FTznrGKZVn6Pd1sHENIc4ZJygpbl3SE96kWMCFvDy2zgLWATvv5xBt9C7oUPAwFxxiqayH2WVXFkxxVQq7gDX2c3IBDqRyB0lvdrjMPibso4XpDXo56inDxeE-Rz-_XP-4-ra6_f715urz7co0XJSV5T1rhDYtp43ph3ZoWwaEt8CBaiv4AC0ZJB0ptWRgcuyJBgDW9HKQgneCn6Obva6N-l5tkvM67VTUTv0txLRWOhVnJlDQAKGy67WRjaAgOyF0VSCGEM6NHKrWx73WZh48WAOh1M96Jvq8E9ydWsetakV1iNIq8P4gkOLDDLko77KBadIBqgOKCVFXr3b2FdrsoSbFnBOMxzGUqCUE6ikEagmBOoSg8t79u-OR9WR5BXzaA1wYY_L6MabJqqJ3U0xj0sG4rPj_Z_wBrezF0A |
CitedBy_id | crossref_primary_10_1080_2162402X_2021_1958589 crossref_primary_10_1371_journal_pone_0248903 crossref_primary_10_1158_1078_0432_CCR_20_3701 crossref_primary_10_3389_fimmu_2022_886683 crossref_primary_10_1136_jitc_2023_008001 crossref_primary_10_1158_2326_6066_CIR_21_0831 crossref_primary_10_1172_JCI171621 crossref_primary_10_1038_s41586_021_03994_2 crossref_primary_10_1158_2767_9764_CRC_23_0384 crossref_primary_10_1038_s42003_020_1083_1 crossref_primary_10_1136_jitc_2021_003721 |
Cites_doi | 10.1111/imr.12614 10.1038/nature13954 10.1128/JVI.49.2.471-478.1984 10.1158/0008-5472.CAN-07-6838 10.1038/35074122 10.1007/s00018-011-0657-y 10.4049/jimmunol.1302972 10.1038/nature22991 10.1172/JCI73639 10.1158/0008-5472.1089.65.3 10.1126/science.aao4572 10.1158/2326-6066.CIR-17-0489 10.1038/srep41960 10.1097/00002371-200003000-00001 10.1186/1471-2164-9-225 10.1093/jnci/djr540 10.1002/ijc.22256 10.3389/fimmu.2018.01638 10.1038/nature12477 10.3389/fmicb.2018.00462 10.1002/hep.30091 10.1126/science.1840703 10.1158/1078-0432.CCR-13-2648 10.4049/jimmunol.162.2.989 10.1038/s41591-018-0266-5 10.1038/nm.4051 10.1126/sciimmunol.aat7061 10.1158/2326-6066.CIR-16-0060 10.1038/nrc3670 10.1038/335448a0 10.1038/cr.2012.1 10.1126/science.7513441 10.1371/journal.pone.0207020 10.1146/annurev-virology-031413-085537 10.1158/0008-5472.CAN-17-3953 10.3389/fmicb.2018.00178 10.1038/nbt.2938 10.1016/j.cell.2018.05.052 10.1158/1078-0432.CCR-14-3197 10.1038/nature22976 10.4049/jimmunol.152.1.106 10.1038/nri2941 10.1126/sciimmunol.aao4310 10.1080/2162402x.2019.1673125 10.1038/nri3405 10.1002/ijc.11649 10.1038/nature14001 10.1038/nm0697-682 10.1016/j.cell.2017.05.035 10.1073/pnas.92.25.11810 10.1038/s41568-019-0116-x 10.1128/JVI.00646-08 10.4049/jimmunol.1501657 10.1038/nrc2355 10.3389/fimmu.2014.00616 10.1016/j.cell.2017.11.043 10.1158/1078-0432.CCR-14-0388 10.3389/fimmu.2018.01538 10.1158/0008-5472.CAN-17-0236 10.3389/fonc.2013.00180 |
ContentType | Journal Article |
Copyright | 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 The Author(s) |
Copyright_xml | – notice: 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 – notice: 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. – notice: 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 The Author(s) |
DBID | 0YH NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1080/2162402X.2020.1758602 |
DatabaseName | Taylor & Francis Open Access PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | X. YE ET AL |
EISSN | 2162-402X |
EndPage | 1758602 |
ExternalDocumentID | oai_doaj_org_article_e5e01689ac6541e6844a8430c0033c6b 10_1080_2162402X_2020_1758602 32923116 1758602 |
Genre | Research Article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Regeneron Pharmaceuticals, Inc |
GroupedDBID | 00X 0R~ 0YH 53G AAKDD ABMYL ABUPF ACENM ACGFS ADBBV ADCVX ADFCX ADING AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS BABNJ BLEHA CCCUG DGEBU DGFLZ EBS EUPTU GROUPED_DOAJ HYE KRBQP KSSTO KTTOD KWAYT KYCEM LJTGL M4Z O9- OK1 RPM TFL TFW UHWXJ ZA5 H13 NPM TDBHL 4.4 AAYXX ABDBF CITATION DEAQA EBD EJD OVD TEORI TNTFI TTHFI 7X8 5PM |
ID | FETCH-LOGICAL-c534t-d39254ac7315c9b7b772e037e3e1ad43be70b61f11d0b26f90aeee2596b643843 |
IEDL.DBID | RPM |
ISSN | 2162-4011 2162-402X |
IngestDate | Fri Oct 04 12:58:02 EDT 2024 Tue Sep 17 21:22:29 EDT 2024 Sat Aug 17 02:14:26 EDT 2024 Fri Aug 23 03:06:00 EDT 2024 Tue Aug 27 13:45:51 EDT 2024 Tue Mar 12 04:25:21 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | tumor antigen TCR p15E endogenous retrovirus single cell sequencing m8 MC38 |
Language | English |
License | open-access: http://creativecommons.org/licenses/by-nc/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c534t-d39254ac7315c9b7b772e037e3e1ad43be70b61f11d0b26f90aeee2596b643843 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458611/ |
PMID | 32923116 |
PQID | 2442597589 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1080_2162402X_2020_1758602 pubmed_primary_32923116 proquest_miscellaneous_2442597589 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7458611 informaworld_taylorfrancis_310_1080_2162402X_2020_1758602 doaj_primary_oai_doaj_org_article_e5e01689ac6541e6844a8430c0033c6b |
PublicationCentury | 2000 |
PublicationDate | 2020-01-01 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncoimmunology |
PublicationTitleAlternate | Oncoimmunology |
PublicationYear | 2020 |
Publisher | Taylor & Francis Taylor & Francis Group |
Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
References | e_1_3_3_52_1 e_1_3_3_50_1 e_1_3_3_18_1 e_1_3_3_39_1 e_1_3_3_14_1 e_1_3_3_37_1 e_1_3_3_16_1 e_1_3_3_35_1 e_1_3_3_58_1 e_1_3_3_10_1 e_1_3_3_33_1 e_1_3_3_56_1 e_1_3_3_12_1 e_1_3_3_31_1 e_1_3_3_54_1 e_1_3_3_40_1 e_1_3_3_61_1 e_1_3_3_7_1 e_1_3_3_9_1 e_1_3_3_29_1 e_1_3_3_25_1 e_1_3_3_48_1 e_1_3_3_27_1 e_1_3_3_46_1 e_1_3_3_3_1 e_1_3_3_21_1 e_1_3_3_44_1 e_1_3_3_5_1 e_1_3_3_23_1 e_1_3_3_42_1 e_1_3_3_30_1 e_1_3_3_51_1 Kershaw MH (e_1_3_3_47_1) 2001; 61 e_1_3_3_17_1 e_1_3_3_19_1 e_1_3_3_13_1 e_1_3_3_38_1 e_1_3_3_59_1 e_1_3_3_15_1 e_1_3_3_36_1 e_1_3_3_57_1 e_1_3_3_34_1 e_1_3_3_55_1 e_1_3_3_11_1 e_1_3_3_32_1 e_1_3_3_53_1 e_1_3_3_41_1 e_1_3_3_62_1 e_1_3_3_60_1 e_1_3_3_6_1 e_1_3_3_8_1 e_1_3_3_28_1 e_1_3_3_24_1 e_1_3_3_49_1 e_1_3_3_26_1 e_1_3_3_2_1 e_1_3_3_20_1 e_1_3_3_45_1 e_1_3_3_4_1 e_1_3_3_22_1 e_1_3_3_43_1 |
References_xml | – ident: e_1_3_3_43_1 doi: 10.1111/imr.12614 – ident: e_1_3_3_4_1 doi: 10.1038/nature13954 – ident: e_1_3_3_35_1 doi: 10.1128/JVI.49.2.471-478.1984 – ident: e_1_3_3_52_1 doi: 10.1158/0008-5472.CAN-07-6838 – ident: e_1_3_3_25_1 doi: 10.1038/35074122 – ident: e_1_3_3_36_1 doi: 10.1007/s00018-011-0657-y – ident: e_1_3_3_37_1 doi: 10.4049/jimmunol.1302972 – volume: 61 start-page: 7920 issue: 21 year: 2001 ident: e_1_3_3_47_1 article-title: Immunization against endogenous retroviral tumor-associated antigens publication-title: Cancer Res contributor: fullname: Kershaw MH – ident: e_1_3_3_22_1 doi: 10.1038/nature22991 – ident: e_1_3_3_32_1 doi: 10.1172/JCI73639 – ident: e_1_3_3_26_1 doi: 10.1158/0008-5472.1089.65.3 – ident: e_1_3_3_5_1 doi: 10.1126/science.aao4572 – ident: e_1_3_3_15_1 doi: 10.1158/2326-6066.CIR-17-0489 – ident: e_1_3_3_54_1 doi: 10.1038/srep41960 – ident: e_1_3_3_29_1 doi: 10.1097/00002371-200003000-00001 – ident: e_1_3_3_42_1 doi: 10.1186/1471-2164-9-225 – ident: e_1_3_3_53_1 doi: 10.1093/jnci/djr540 – ident: e_1_3_3_55_1 doi: 10.1002/ijc.22256 – ident: e_1_3_3_7_1 doi: 10.3389/fimmu.2018.01638 – ident: e_1_3_3_3_1 doi: 10.1038/nature12477 – ident: e_1_3_3_49_1 doi: 10.3389/fmicb.2018.00462 – ident: e_1_3_3_61_1 doi: 10.1002/hep.30091 – ident: e_1_3_3_16_1 doi: 10.1126/science.1840703 – ident: e_1_3_3_10_1 doi: 10.1158/1078-0432.CCR-13-2648 – ident: e_1_3_3_46_1 doi: 10.4049/jimmunol.162.2.989 – ident: e_1_3_3_13_1 doi: 10.1038/s41591-018-0266-5 – ident: e_1_3_3_45_1 doi: 10.1038/nm.4051 – ident: e_1_3_3_28_1 doi: 10.1126/sciimmunol.aat7061 – ident: e_1_3_3_30_1 doi: 10.1158/2326-6066.CIR-16-0060 – ident: e_1_3_3_11_1 doi: 10.1038/nrc3670 – ident: e_1_3_3_39_1 doi: 10.1038/335448a0 – ident: e_1_3_3_44_1 doi: 10.1038/cr.2012.1 – ident: e_1_3_3_18_1 doi: 10.1126/science.7513441 – ident: e_1_3_3_27_1 doi: 10.1371/journal.pone.0207020 – ident: e_1_3_3_41_1 doi: 10.1146/annurev-virology-031413-085537 – ident: e_1_3_3_62_1 doi: 10.1158/0008-5472.CAN-17-3953 – ident: e_1_3_3_50_1 doi: 10.3389/fmicb.2018.00178 – ident: e_1_3_3_8_1 doi: 10.1038/nbt.2938 – ident: e_1_3_3_60_1 doi: 10.1016/j.cell.2018.05.052 – ident: e_1_3_3_51_1 doi: 10.1158/1078-0432.CCR-14-3197 – ident: e_1_3_3_23_1 doi: 10.1038/nature22976 – ident: e_1_3_3_34_1 doi: 10.4049/jimmunol.152.1.106 – ident: e_1_3_3_6_1 doi: 10.1038/nri2941 – ident: e_1_3_3_14_1 doi: 10.1126/sciimmunol.aao4310 – ident: e_1_3_3_21_1 doi: 10.1080/2162402x.2019.1673125 – ident: e_1_3_3_38_1 doi: 10.1038/nri3405 – ident: e_1_3_3_58_1 doi: 10.1002/ijc.11649 – ident: e_1_3_3_20_1 doi: 10.1038/nature14001 – ident: e_1_3_3_24_1 doi: 10.1038/nm0697-682 – ident: e_1_3_3_9_1 doi: 10.1016/j.cell.2017.05.035 – ident: e_1_3_3_17_1 doi: 10.1073/pnas.92.25.11810 – ident: e_1_3_3_2_1 doi: 10.1038/s41568-019-0116-x – ident: e_1_3_3_57_1 doi: 10.1128/JVI.00646-08 – ident: e_1_3_3_48_1 doi: 10.4049/jimmunol.1501657 – ident: e_1_3_3_12_1 doi: 10.1038/nrc2355 – ident: e_1_3_3_40_1 doi: 10.3389/fimmu.2014.00616 – ident: e_1_3_3_19_1 doi: 10.1016/j.cell.2017.11.043 – ident: e_1_3_3_56_1 doi: 10.1158/1078-0432.CCR-14-0388 – ident: e_1_3_3_31_1 doi: 10.3389/fimmu.2018.01538 – ident: e_1_3_3_33_1 doi: 10.1158/0008-5472.CAN-17-0236 – ident: e_1_3_3_59_1 doi: 10.3389/fonc.2013.00180 |
SSID | ssj0000605639 |
Score | 2.3170416 |
Snippet | Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden... |
SourceID | doaj pubmedcentral proquest crossref pubmed informaworld |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1758602 |
SubjectTerms | endogenous retrovirus MC38 Original Research p15E single cell sequencing TCR tumor antigen |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PaxwhFJYQKORSmiZtpz-ChV4nGUdH12NaEkIgPTWwN1HnDZ1D3HbjQvPf96kzYTcUcilzc9RR33P8fPq-R8gXzbgFuRA1852thVC6diI55wxS9NoBiBy15Oa7vLoV18tuuRXqK90JK_TAZeDOoANEJQttfYpYnaoVdiF441MUMi9d_vuybmszVf7BuLBzPbvsLJqzlsl0kLDELWGLSQiT5WRKmRejzNn_hLH0X7jz6fXJrfXo8hV5OQFJel46cEj2ILwmL0poyYcj8uci9KtCwErXEJPhACuhmZZhDPd08sCjNtAxuYjg7rRciqFuE2lYRSz1ezOms2XMExNnJx0DtfQumedhKlS8tx5o3Nyt1jRH1Tkmt5cXP75d1VOUhdp3XMS6R4TUCesVZ53XTjnE29BwBRyY7QV3oBon2cBY37hWDrqxAIC7JukQzaAo3pD9sArwjlCH66C3w9CwgYtBKyc56J6rpnX4CF-R03m4za9CpmHYxFE6y8ck-ZhJPhX5moTymDlxYecE1BAzaYh5TkMqordFamI2hQwlbonhzzTg8yx_g_MuHabYACg6g7AIxwBz6Yq8Lfrw2EzeJtjMZEXUjqbs9GP3TRh_Zm5vJfC7jL3_Hx3_QA5SX4rB6CPZj-sNfEIIFd1Jni1_ARyfF2g priority: 102 providerName: Directory of Open Access Journals – databaseName: Taylor & Francis Open Access dbid: 0YH link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQERIXVN7hJSNxDdix46yPgFqtkOBEpXKy7GQCOdSBXa9E_31n4mTVrUAcUE5J7MTxjOPP45lvGHtjpfJgVrqUbe1LrRtbBk3BOb3RnQ0Aespa8vmLWZ_pT-f14k24nd0qaQ3dZ6KI6V9Ng9uH7eIR966ShvYEznF1V-ElRLyG6CRvVwi9SdXFt_XezCIQruMkvMTu_K32waw0kfffoC79EwC96Ud5bWI6PWb3ZkTJ32cVuM9uQXzA7uQck5cP2e-T2I2ZiZVvIJEFAR_CJ36GIW75HIrHfeQDxYrgMjV7x_CwSzyOCWv92g20yYxlEpF38iFyzy_ITg9zpRzGdcnT7mLc8Cm9ziN2dnry9eO6nNMtlG2tdCo7hEq19m2jZN3a0AQE3iBUAwqk77QK0IhgZC9lJ0Jleis8AODyyQSENSutHrOjOEZ4ynjACbH1fS9kr3Rvm2AU2E41ogp46LZgb5fudj8zq4aTM1npIh9H8nGzfAr2gYSyL0yk2NOFcfPdzWPMQQ0IYFfWt5TcnDRQe2yWaClhXWtCwex1kbo02UT6nMDEqX804PUif4cDkHZVfAQUnUN8hH2ApWzBnmR92DdTVYSfpSlYc6ApB99xeCcOPyaS70bje6V89h9tfs7u0mk2GL1gR2mzg5cIoVJ4NQ2SK-mlFYg priority: 102 providerName: Taylor & Francis |
Title | Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model |
URI | https://www.tandfonline.com/doi/abs/10.1080/2162402X.2020.1758602 https://www.ncbi.nlm.nih.gov/pubmed/32923116 https://search.proquest.com/docview/2442597589 https://pubmed.ncbi.nlm.nih.gov/PMC7458611 https://doaj.org/article/e5e01689ac6541e6844a8430c0033c6b |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA-3B4Iv4rf1Y4nga3eTTZo0j3rcsQgnPniwPoUkTbXgpufaBe-_d5K0x-4hCNK3NGmTzrT5zXRmfgi9U5QZL2peUleZknOpSstjck4reKOs9zyxllx-Eusr_nFTbU5QNeXCpKB9Z7tF-LFdhO57iq283rrlFCe2_Hx5JnlVC0qXMzSTjB2Y6PnzC3t6YhBb0XhTUOApc6cmy9gGJtMGLMMVNAFaFiQy2rBVRDqR9fxge0pV_O_UMP0bEr0bUHmwQ108RA9GaInf5yU8Qic-PEb3MtnkzRP0-zw0fS7Jind-iK4EuAhOhRq68AuPOXnYBNzFpBGwV3OYDLb7AYd-gFE_91382wx9hljFE3cBG7yNDns_Dsr5XDd42G_7HU48O0_R1cX5l7N1OfIulK5ifCgbwEwVN04yWjllpQUE7gmTnnlqGs6sl8QK2lLaELsSrSLGew92lLCAb2rOnqHT0Af_AmELO6MzbUtoy3irpBXMq4ZJsrJwcFegxfS49XUur6HpWLV0EpWOotKjqAr0IQrltnOsjp0a-t03PeqI9pUHJFsr4yLLeVRFbmBaxEXmOidsgdShSPWQnCNtZjLR7B8TeDvJX8ObGH-vmOBBdBqAEjwD6KUK9Dzrw-00J_UqkDzSlKN1HJ8B5U_Vvkdlf_nfI1-h-3EB2W_0Gp0Ou71_A0hqsHM0I1_X8-SHmKe36A9DtRym |
link.rule.ids | 230,315,733,786,790,870,891,2115,27533,27955,27956,53825,53827,59496,59497 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj9QgFCbrGqMv3i_1iomv7ZRCb4-62c2oOxsfds28EaB0bXToOtLE9dd7gHYzMzExmnmjkIHyUc6Bc74PoTc1oUIXFYuJykXMWFnHkrnknLZgTS21Zl61ZHFSzM_Yh2W-3EP5lAvjg_aV7BLzbZWY7ouPrbxYqdkUJzb7tDgoWV4VhMyuoeuwXrN8w0kPH2DY1b2GWEbc3wKEp9ydKp25MnCaluAbZlAE9nKROk0bmjlbx-meb2xQnsd_h8X0T7bobkjlxh51dAd9nkYXQlO-JoOVifq1Q_z4z8O_i26PVit-Gx7fQ3va3Ec3go7l5QP089A0fWB7xWtt3SkF9A57DojO_MBjuh8WBncuHwVc4RCBg-VgsekttPo-dO4iG-pYRxCKO4MFXrm7AD02Cqlil9gOq36NvYTPQ3R2dHh6MI9HSYdY5ZTZuAFzLGdClZTkqpalBONep7TUVBPRMCp1mcqCtIQ0qcyKtk6F1hpctEKC6VQx-gjtm97oJwhL2HSVaNuUtJS1dSkLquuGlmkm4cdUhJJpHvlFYO7gZCREnTDAHQb4iIEIvXOzfVXZEW_7gn59zsf3z3WuwUiuaqGcgLpDORPQrVQ5UTxVyAjVm1jh1p-7tEEkhdO_dOD1BCwOi9zd3AijYeo42GDwDqBWHaHHAWhX3ZxwG6FyC4Jb49h-AsDyROIjkJ7-d8tX6Ob8dHHMj9-ffHyGbrnBhOOp52jfrgf9Agw2K1_65fkbNjA8tQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagCMSFnRJWI3HN4tjZjlA6KkurHqg04mLZjgMRHWcYEony63m2kyozQkKq5uaxFTv-HH_Pfu99CL2pCBU6L1lIVCZCxooqlMwG5zQ5qyupNXOqJccn-dEZ-7jMljOpL-e0r2QbmfNVZNrvzrdyvVLx5CcWnx4fFCwrc0Lidd3E19ENWLNpMTPU_UcYdnanI5YS-2iA8RS_UyaxLQPDaQn2YQpFwJnzxOra0NTyHat9PtukXC7_nUym_-Kju26Vs31qcRd9nUbo3VN-REMvI_VnJ_njlV7BPXRnZK_4ra9yH13T5gG66fUsLx6i34em7nzWV7zRvT2tgB5ilwuiNb_wGPaHhcGtjUsBk9h74mA59Nh0PbT6ObT2Qhvq9DZRKG4NFnhl7wT02MiHjF3gflh1G-ykfB6hs8Xhl4OjcJR2CFVGWR_WQMsyJlRBSaYqWUgg-TqhhaaaiJpRqYtE5qQhpE5kmjdVIrTWYKrlEihUyehjtGc6o58gLGHzVaJpEtJQ1lSFzKmualokqYQfUwGKprnka5_Bg5MxMeqEA25xwEccBOidnfHLyjYBtyvoNt_4OAdcZxrIclkJZYXULdqZgG4lyorjqVwGqJrjhffu_KXxYimc_qcDrydwcVjs9gZHGA1Tx4GLwTuAWlWA9j3YLrs5YTdAxRYMt8ax_Q-AyyUUH8H09MotX6Fbp-8X_POHk0_P0G07Fn9K9Rzt9ZtBvwDe1suXboX-BRwvPzU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Endogenous+retroviral+proteins+provide+an+immunodominant+but+not+requisite+antigen+in+a+murine+immunotherapy+tumor+model&rft.jtitle=Oncoimmunology&rft.au=Ye%2C+Xuan&rft.au=Waite%2C+Janelle+C&rft.au=Dhanik%2C+Ankur&rft.au=Gupta%2C+Namita&rft.date=2020-01-01&rft.issn=2162-4011&rft.volume=9&rft.issue=1&rft.spage=1758602&rft_id=info:doi/10.1080%2F2162402X.2020.1758602&rft_id=info%3Apmid%2F32923116&rft.externalDocID=32923116 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-4011&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-4011&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-4011&client=summon |